Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples

NCT ID: NCT03020121

Last Updated: 2018-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-30

Study Completion Date

2017-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to compare the results of the Becton Dickinson (BD) Human Papilloma Virus (HPV) Assay on the Viper LT instrument from Liquid-based cytology media diluted in HPV diluent to adjudicated histology results from biopsy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uterine Cervical Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BD HPV assay on Viper LT

The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.

Device: BD HPV assay on Viper LT The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test. Colposcopy/biopsy will be performed on all subjects.

Group Type EXPERIMENTAL

Colposcopy/biopsy

Intervention Type PROCEDURE

Colposcopy/biopsy will be performed on all subjects

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Colposcopy/biopsy

Colposcopy/biopsy will be performed on all subjects

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Females who are greater than or equal to 21 years of age,
* Subjects with a ASCUS (Atypical Squamous Cells - Undetermined Significance) cytology result,
* Females who provide informed consent

Exclusion Criteria

* Known pregnant
* Prior complete or partial hysterectomy involving removal of cervix
* Conization, LEEP, cervical laser surgery or cryosurgery on the cervix has been performed in the last twelve months
* Colposcopy clinic referral patients
Minimum Eligible Age

21 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Becton, Dickinson and Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Planned Parenthood of the Rocky Mountains

Denver, Colorado, United States

Site Status

American Pathology Partners Inc.

Denver, Colorado, United States

Site Status

Comprehensive Clinical Trials, LLC

West Palm Beach, Florida, United States

Site Status

Indiana University

Indianapolis, Indiana, United States

Site Status

Sidney & Lois Eskenazi Hospital

Indianapolis, Indiana, United States

Site Status

Transgenomics

Omaha, Nebraska, United States

Site Status

Southwest Womens Health

Albuquerque, New Mexico, United States

Site Status

Tricore Reference Lab

Albuquerque, New Mexico, United States

Site Status

Research Pathology Associates, LLC

Irvington, New York, United States

Site Status

Research Pathology Associates

Charlotte, North Carolina, United States

Site Status

Center for Disease Detection

San Antonio, Texas, United States

Site Status

BioVision

Outremont, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BDS-USHPVPC-AC

Identifier Type: -

Identifier Source: org_study_id